Literature DB >> 25828456

Interpreting important health-related quality of life change using the Haem-A-QoL.

K W Wyrwich1, S Krishnan2, J L Poon1, P Auguste1, R von Maltzahn1, R Yu1, S von Mackensen3.   

Abstract

The Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) measures health-related quality of life (HRQoL) in adults with haemophilia; however, change score thresholds for identifying individuals experiencing a HRQoL benefit have not been appropriately investigated. The objective of this analysis was to derive appropriate HRQoL responder definitions (RDs) for two Haem-A-QoL domains that reflect key impairments, 'Physical Health' and 'Sports & Leisure,' and the Haem-A-QoL 'Total Score' using anchor- and distribution-based methods. In this analysis, data from adults in A-LONG and B-LONG, two Phase 3 clinical studies of rFVIIIFc in haemophilia A and rFIXFc in haemophilia B, respectively, were used. The anchor-based approach identified Haem-A-QoL changes corresponding to EQ-5D item improvements between baseline and 6 months; the distribution-based methods examined the magnitude at baseline of one-half standard deviation and the standard error of measurement. Through triangulation, the most appropriate RDs were derived. Of the 133 A-LONG and 73 B-LONG subjects with baseline Haem-A-QoL scores, 67 and 51 subjects, respectively, completed the Haem-A-QoL questionnaire at both baseline and 6 months follow-up. Triangulation of anchor- and distribution-based estimates with the observed Haem-A-QoL change scores identified a 10-point reduction in the 'Physical Health' and 'Sports & Leisure' domains, and a 7-point reduction in 'Total Score' as the RD thresholds most indicative of HRQoL benefit. These empirically derived RDs for two key Haem-A-QoL domains and 'Total Score' are reasonable and practical thresholds for identifying subjects with notable improvements in HRQoL, and provides HRQoL RDs that can be used for further analysis and interpretation of data from haemophilia clinical trials.
© 2015 Evidera, Inc. Haemophilia published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Haem-A-QoL; clinical trial; haemophilia; minimal clinically important difference; quality of life; responder definition

Mesh:

Year:  2015        PMID: 25828456     DOI: 10.1111/hae.12642

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  9 in total

1.  The effects of joint disease, inhibitors and other complications on health-related quality of life among males with severe haemophilia A in the United States.

Authors:  J M Soucie; S D Grosse; A-E-A Siddiqi; V Byams; J Thierry; M M Zack; A Shapiro; N Duncan
Journal:  Haemophilia       Date:  2017-06-02       Impact factor: 4.287

2.  Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.

Authors:  K John Pasi; Michael Laffan; Savita Rangarajan; Tara M Robinson; Nina Mitchell; Will Lester; Emily Symington; Bella Madan; Xinqun Yang; Benjamin Kim; Glenn F Pierce; Wing Yen Wong
Journal:  Haemophilia       Date:  2021-08-11       Impact factor: 4.263

3.  Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.

Authors:  K John Pasi; Toshko Lissitchkov; Vasily Mamonov; Tim Mant; Margarita Timofeeva; Catherine Bagot; Pratima Chowdary; Pencho Georgiev; Liana Gercheva-Kyuchukova; Kate Madigan; Huy Van Nguyen; Qifeng Yu; Baisong Mei; Craig C Benson; Margaret V Ragni
Journal:  J Thromb Haemost       Date:  2021-05-18       Impact factor: 5.824

4.  Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial.

Authors:  Runhui Wu; Jing Sun; Weiqun Xu; Qun Hu; Wenqian Li; Jianwen Xiao; Feng'e Yang; Xiaojing Zeng; Yun Zeng; Jianfeng Zhou; Irina Matytsina; Sali Zhang; Michael Pluta; Renchi Yang
Journal:  Ther Clin Risk Manag       Date:  2020-06-23       Impact factor: 2.423

5.  Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).

Authors:  Johnny Mahlangu; Johannes Oldenburg; Michael U Callaghan; Midori Shima; Maria Elisa Mancuso; Peter Trask; Michael Recht; Claudia Garcia; Renchi Yang; Michaela Lehle; Harrison Macharia; Elina Asikanius; Gallia G Levy; Rebecca Kruse-Jarres; Sylvia von Mackensen
Journal:  Haemophilia       Date:  2019-04-24       Impact factor: 4.287

6.  The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B.

Authors:  Haowei Linda Sun; Ming Yang; Man-Chiu Poon; Adrienne Lee; K Sue Robinson; Michelle Sholzberg; John Wu; Alfonso Iorio; Victor Blanchette; Manuel Carcao; Robert J Klaassen; Shannon Jackson
Journal:  Res Pract Thromb Haemost       Date:  2021-10-11

7.  Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study.

Authors:  John Pasi; Cédric Hermans; Zalmai Hakimi; Jameel Nazir; Samuel Aballéa; Monia Ezzalfani; Francis Fatoye
Journal:  Ther Adv Hematol       Date:  2022-02-26

8.  Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5).

Authors:  Renchi Yang; Shujie Wang; Xuefeng Wang; Jing Sun; Ampaiwan Chuansumrit; Jianfeng Zhou; Christophe Schmitt; Wanling Hsu; Jeffrey Xu; Lindong Li; Tiffany Chang; Xielan Zhao
Journal:  Res Pract Thromb Haemost       Date:  2022-03-07

9.  Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes.

Authors:  Stacy E Croteau; Allison P Wheeler; Osman Khan; Kristina M Haley; Alexandra J Borst; Susan Lattimore; Cindy H T Yeung; Alfonso Iorio
Journal:  Res Pract Thromb Haemost       Date:  2020-02-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.